Calcium Phosphate Cement Paste Injection as a Fiducial Marker of Cervical Cancer

Ogino, Ichiro; Kitagawa, Masakazu; Watanabe, Shun-ichi; Yoshida, Hiroshi; Hata, Masaharu

doi:10.21873/invivo.11421

Cited by 1 publication

(2 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Tumor growth was inhibited for both the treated/primary tumor and the untreated secondary tumor in both sets of studies shown in Figure 4 b–e. Response in treatment groups without radiation highlights the fact, also seen in other studies, that anti-CD40 itself can cause immunogenic cell death and in situ vaccination [ 35 , 36 ].…”

Section: Resultssupporting

confidence: 65%

“…Meanwhile, previous work has investigated novel fiducials for use during cervical cancer radiotherapy. For example, a calcium phosphate cement (CPC) marker was investigated as an injectable non-metallic fiducial marker [ 35 ]. This study, conducted in six patients receiving 3–5 injections of the CPC markers, demonstrated that such fiducials injected into cervical tumors can be visualized on cone beam computed tomography (CT) and MRI with reductions in marker loss and artifacts [ 33 ].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Investigating the Use of a Liquid Immunogenic Fiducial Eluter Biomaterial in Cervical Cancer Treatment

Moreau,

Keno,

China

et al. 2024

Cancers

View full text Add to dashboard Cite

Globally, cervical cancer is the fourth leading cancer among women and is dominant in resource-poor settings in its occurrence and mortality. This study focuses on developing liquid immunogenic fiducial eluter (LIFE) Biomaterial with components that include biodegradable polymers, nanoparticles, and an immunoadjuvant. LIFE Biomaterial is designed to provide image guidance during radiotherapy similar to clinically used liquid fiducials while enhancing therapeutic efficacy for advanced cervical cancer. C57BL6 mice were used to grow subcutaneous tumors on bilateral flanks. The tumor on one flank was then treated using LIFE Biomaterial prepared with the immunoadjuvant anti-CD40, with/without radiotherapy at 6 Gy. Computed tomography (CT) and magnetic resonance (MR) imaging visibility were also evaluated in human cadavers. A pharmacodynamics study was also conducted to assess the safety of LIFE Biomaterial in healthy C57BL6 female mice. Results showed that LIFE Biomaterial could provide both CT and MR imaging contrast over time. Inhibition in tumor growth and prolonged significant survival (* p < 0.05) were consistently observed for groups treated with the combination of radiotherapy and LIFE Biomaterial, highlighting the potential for this strategy. Minimal toxicity was observed for healthy mice treated with LIFE Biomaterial with/without anti-CD40 in comparison to non-treated cohorts. The results demonstrate promise for the further development and clinical translation of this approach to enhance the survival and quality of life of patients with advanced cervical cancer.

show abstract

Section: Resultssupporting

confidence: 65%

Section: Introductionmentioning

confidence: 99%